In this regard, fourth-generation CARs (referred to as “armored” CARs) that incorporate cytokines (IL-7, IL-15, or IL-21) are being developed to improve CAR-T cell persistence, tumor targeting, and antitumor capacity8–12. This evidence concerns the gene IL7 and neoplasm.